Cargando…

A prognostic score for patients with acute-on-chronic liver failure treated with plasma exchange-centered artificial liver support system

Artificial liver support system (ALSS) therapy is widely used in patients with hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF). We aimed to develop a predictive score to identify the subgroups who may benefit from plasma exchange (PE)-centered ALSS therapy. A total of 601 patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Du, Lingyao, Ma, Yuanji, Zhou, Shaoqun, Chen, Fang, Xu, Yan, Wang, Ming, Lei, Xuezhong, Feng, Ping, Tang, Hong, Bai, Lang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7809456/
https://www.ncbi.nlm.nih.gov/pubmed/33446902
http://dx.doi.org/10.1038/s41598-021-81019-8
_version_ 1783637126760366080
author Du, Lingyao
Ma, Yuanji
Zhou, Shaoqun
Chen, Fang
Xu, Yan
Wang, Ming
Lei, Xuezhong
Feng, Ping
Tang, Hong
Bai, Lang
author_facet Du, Lingyao
Ma, Yuanji
Zhou, Shaoqun
Chen, Fang
Xu, Yan
Wang, Ming
Lei, Xuezhong
Feng, Ping
Tang, Hong
Bai, Lang
author_sort Du, Lingyao
collection PubMed
description Artificial liver support system (ALSS) therapy is widely used in patients with hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF). We aimed to develop a predictive score to identify the subgroups who may benefit from plasma exchange (PE)-centered ALSS therapy. A total of 601 patients were retrospectively enrolled and randomly divided into a derivation cohort of 303 patients and a validation cohort of 298 patients for logistic regression analysis, respectively. Five baseline variables, including liver cirrhosis, total bilirubin, international normalized ratio of prothrombin time, infection and hepatic encephalopathy, were found independently associated with 3-month mortality. A predictive PALS model and the simplified PALS score were developed. The predicative value of PALS score (AUROC = 0.818) to 3-month prognosis was as capable as PALS model (AUROC = 0.839), R score (AUROC = 0.824) and Yue-Meng’ score (AUROC = 0.810) (all p > 0.05), and superior to CART model (AUROC = 0.760) and MELD score (AUROC = 0.765) (all p < 0.05). The PALS score had significant linear correlation with 3-month mortality (R(2) = 0.970, p = 0.000). PALS score of 0–2 had both sensitivity and negative predictive value of > 90% for 3-month mortality, while PALS score of 6–9 had both specificity and positive predictive value of > 90%. Patients with PALS score of 3–5 who received 3–5 sessions of ALSS therapy had much lower 3-month mortality than those who received 1–2 sessions (32.8% vs. 59.2%, p < 0.05). The more severe patients with PALS score of 6–9 could still benefit from ≥ 6 sessions of ALSS therapy compared to ≤ 2 sessions (63.6% vs. 97.0%, p < 0.05). The PALS score could predict prognosis reliably and conveniently. It could identify the subgroups who could benefit from PE-centered ALSS therapy, and suggest the reasonable sessions. Trial registration: Chinese Clinical Trial Registry, ChiCTR2000032055. Registered 19th April 2020, http://www.chictr.org.cn/showproj.aspx?proj=52471.
format Online
Article
Text
id pubmed-7809456
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-78094562021-01-21 A prognostic score for patients with acute-on-chronic liver failure treated with plasma exchange-centered artificial liver support system Du, Lingyao Ma, Yuanji Zhou, Shaoqun Chen, Fang Xu, Yan Wang, Ming Lei, Xuezhong Feng, Ping Tang, Hong Bai, Lang Sci Rep Article Artificial liver support system (ALSS) therapy is widely used in patients with hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF). We aimed to develop a predictive score to identify the subgroups who may benefit from plasma exchange (PE)-centered ALSS therapy. A total of 601 patients were retrospectively enrolled and randomly divided into a derivation cohort of 303 patients and a validation cohort of 298 patients for logistic regression analysis, respectively. Five baseline variables, including liver cirrhosis, total bilirubin, international normalized ratio of prothrombin time, infection and hepatic encephalopathy, were found independently associated with 3-month mortality. A predictive PALS model and the simplified PALS score were developed. The predicative value of PALS score (AUROC = 0.818) to 3-month prognosis was as capable as PALS model (AUROC = 0.839), R score (AUROC = 0.824) and Yue-Meng’ score (AUROC = 0.810) (all p > 0.05), and superior to CART model (AUROC = 0.760) and MELD score (AUROC = 0.765) (all p < 0.05). The PALS score had significant linear correlation with 3-month mortality (R(2) = 0.970, p = 0.000). PALS score of 0–2 had both sensitivity and negative predictive value of > 90% for 3-month mortality, while PALS score of 6–9 had both specificity and positive predictive value of > 90%. Patients with PALS score of 3–5 who received 3–5 sessions of ALSS therapy had much lower 3-month mortality than those who received 1–2 sessions (32.8% vs. 59.2%, p < 0.05). The more severe patients with PALS score of 6–9 could still benefit from ≥ 6 sessions of ALSS therapy compared to ≤ 2 sessions (63.6% vs. 97.0%, p < 0.05). The PALS score could predict prognosis reliably and conveniently. It could identify the subgroups who could benefit from PE-centered ALSS therapy, and suggest the reasonable sessions. Trial registration: Chinese Clinical Trial Registry, ChiCTR2000032055. Registered 19th April 2020, http://www.chictr.org.cn/showproj.aspx?proj=52471. Nature Publishing Group UK 2021-01-14 /pmc/articles/PMC7809456/ /pubmed/33446902 http://dx.doi.org/10.1038/s41598-021-81019-8 Text en © The Author(s) 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Du, Lingyao
Ma, Yuanji
Zhou, Shaoqun
Chen, Fang
Xu, Yan
Wang, Ming
Lei, Xuezhong
Feng, Ping
Tang, Hong
Bai, Lang
A prognostic score for patients with acute-on-chronic liver failure treated with plasma exchange-centered artificial liver support system
title A prognostic score for patients with acute-on-chronic liver failure treated with plasma exchange-centered artificial liver support system
title_full A prognostic score for patients with acute-on-chronic liver failure treated with plasma exchange-centered artificial liver support system
title_fullStr A prognostic score for patients with acute-on-chronic liver failure treated with plasma exchange-centered artificial liver support system
title_full_unstemmed A prognostic score for patients with acute-on-chronic liver failure treated with plasma exchange-centered artificial liver support system
title_short A prognostic score for patients with acute-on-chronic liver failure treated with plasma exchange-centered artificial liver support system
title_sort prognostic score for patients with acute-on-chronic liver failure treated with plasma exchange-centered artificial liver support system
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7809456/
https://www.ncbi.nlm.nih.gov/pubmed/33446902
http://dx.doi.org/10.1038/s41598-021-81019-8
work_keys_str_mv AT dulingyao aprognosticscoreforpatientswithacuteonchronicliverfailuretreatedwithplasmaexchangecenteredartificialliversupportsystem
AT mayuanji aprognosticscoreforpatientswithacuteonchronicliverfailuretreatedwithplasmaexchangecenteredartificialliversupportsystem
AT zhoushaoqun aprognosticscoreforpatientswithacuteonchronicliverfailuretreatedwithplasmaexchangecenteredartificialliversupportsystem
AT chenfang aprognosticscoreforpatientswithacuteonchronicliverfailuretreatedwithplasmaexchangecenteredartificialliversupportsystem
AT xuyan aprognosticscoreforpatientswithacuteonchronicliverfailuretreatedwithplasmaexchangecenteredartificialliversupportsystem
AT wangming aprognosticscoreforpatientswithacuteonchronicliverfailuretreatedwithplasmaexchangecenteredartificialliversupportsystem
AT leixuezhong aprognosticscoreforpatientswithacuteonchronicliverfailuretreatedwithplasmaexchangecenteredartificialliversupportsystem
AT fengping aprognosticscoreforpatientswithacuteonchronicliverfailuretreatedwithplasmaexchangecenteredartificialliversupportsystem
AT tanghong aprognosticscoreforpatientswithacuteonchronicliverfailuretreatedwithplasmaexchangecenteredartificialliversupportsystem
AT bailang aprognosticscoreforpatientswithacuteonchronicliverfailuretreatedwithplasmaexchangecenteredartificialliversupportsystem
AT dulingyao prognosticscoreforpatientswithacuteonchronicliverfailuretreatedwithplasmaexchangecenteredartificialliversupportsystem
AT mayuanji prognosticscoreforpatientswithacuteonchronicliverfailuretreatedwithplasmaexchangecenteredartificialliversupportsystem
AT zhoushaoqun prognosticscoreforpatientswithacuteonchronicliverfailuretreatedwithplasmaexchangecenteredartificialliversupportsystem
AT chenfang prognosticscoreforpatientswithacuteonchronicliverfailuretreatedwithplasmaexchangecenteredartificialliversupportsystem
AT xuyan prognosticscoreforpatientswithacuteonchronicliverfailuretreatedwithplasmaexchangecenteredartificialliversupportsystem
AT wangming prognosticscoreforpatientswithacuteonchronicliverfailuretreatedwithplasmaexchangecenteredartificialliversupportsystem
AT leixuezhong prognosticscoreforpatientswithacuteonchronicliverfailuretreatedwithplasmaexchangecenteredartificialliversupportsystem
AT fengping prognosticscoreforpatientswithacuteonchronicliverfailuretreatedwithplasmaexchangecenteredartificialliversupportsystem
AT tanghong prognosticscoreforpatientswithacuteonchronicliverfailuretreatedwithplasmaexchangecenteredartificialliversupportsystem
AT bailang prognosticscoreforpatientswithacuteonchronicliverfailuretreatedwithplasmaexchangecenteredartificialliversupportsystem